Q-omics provides the consensus-scored PATL2 profile across patient tissues and cancer cell-line models. PATL2 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, PATL2 is differentially expressed in 9, with the highest sampling consensus in KIRC. Additionally, PATL2 RNA expression shows 17,631 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight SKCM, KIRC, and UVM as cancer lineages where PATL2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PATL2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PATL2 survival associations across molecular data types. PATL2 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PATL2 RNA expression–survival associations across cancer types. High PATL2 expression shows unfavorable associations in UVM, KIRC and THYM, but favorable associations in SKCM, BLCA and CESC. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for PATL2 RNA expression.
This table summarizes PATL2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for PATL2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PATL2 shows lower tumor expression in LUSC and higher tumor expression in KIRC, KICH, STAD, KIRP and HNSC. The KIRC box plot shows higher PATL2 RNA expression in tumor versus normal tissue (log2 FC = +0.748, t-test p < 0.001).
This table shows molecular features associated with PATL2 in patient tissues and cancer cell lines. In patient samples, PATL2 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, PATL2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and STOMACH.
